2026-10-27 21:23:00 UTC#524434newconfirmednews
SPRO stock news
SPRO stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-08 20:08:48 UTC#434911newconfirmedpress release
Spruce Biosciences (SPRB) to present natural history data for MPS IIIB at Child Neurology Society meeting
2026-09-17 15:04:00 UTC#328418newconfirmednews
Lake Street initiates coverage of Spruce Biosciences (SPRB) with Buy rating
dow_jonesimportance 0.30trust 0.70Spruce Biosciences, Inc. +0.40Lake Street Capital Markets, LLC +0.40
2026-09-15 18:43:28 UTC#316164duplicateconfirmednews
SPRO details SP001 mechanism and 2027 Phase II trial plans for IgG4-related disease
2026-09-15 18:25:52 UTC#316089newconfirmednews
SPRO plans 2027 Phase II trial for SP001 in IgG4-related disease
2026-08-28 21:33:06 UTC#237458newconfirmednews
Spero Therapeutics establishes $100M ATM equity program with Jefferies, terminates Cantor agreement
tradingviewimportance 0.40trust 0.80Spero Therapeutics, Inc. -0.30Jefferies Financial Group Inc. +0.10Cantor Fitzgerald, L.P. 0
2026-08-13 02:47:53 UTC#169027newconfirmednews
Spero Therapeutics secures $105M royalty financing, extends cash runway into 2H 2029
2026-08-12 22:10:58 UTC#168188duplicateconfirmednews
Spruce Biosciences (SPRO) secures FDA approval for Utebzi and $105M financing, extends runway to 2029
2026-08-12 21:51:57 UTC#168129newconfirmednews
Spruce Biosciences (SPRO) gains FDA approval for Utebzi, secures $105M financing and in-licenses SP001
2026-08-12 20:14:17 UTC#167470newconfirmednews
Spero Therapeutics reports Q2 2026 GAAP EPS of -$0.16
2026-08-12 13:15:37 UTC#165404duplicateconfirmednews
Spruce Biosciences confirms TA-ERT BLA submission and confirmatory study for Q4 2026
2026-08-12 13:05:44 UTC#165312newconfirmednews
Spruce Biosciences reports Q2 2026 GAAP EPS of -$6.68
2026-08-12 13:00:00 UTC#165348duplicateconfirmedpress release
Spruce Biosciences Reports Q2 2026 Loss of $16.2M, $6.68/Shr; Plans BLA for TA-ERT in Q4 2026
dow_jonesimportance 0.30trust 1.00Spruce Biosciences, Inc. -0.20Adrian Quartel +0.10Jessica Cohen Pfeffer +0.10+2 entities
2026-08-12 13:00:00 UTC#165347duplicateconfirmednews
Spruce Biosciences reports Q2 2026 loss of $6.68 per share
2026-08-11 11:00:26 UTC#158225newforecastnews
Spero Therapeutics (SPRO) Q2 2026 Earnings Preview: Analysts Expect $0.17 Loss Per Share
2026-08-10 11:00:05 UTC#152170newconfirmednews
Spruce Biosciences (SPRB) Q2 2026 Earnings Preview: Zero Revenue Expected, EPS Loss of $5.79
2026-07-27 12:03:00 UTC#81636newconfirmedpress release
Spero Therapeutics appoints Debra Jeske Zack as Chief Medical Officer
2026-07-27 12:01:00 UTC#81675newconfirmedpress release
Spruce Biosciences appoints Adrian Quartel as Chief Medical Officer
2026-07-14 12:28:42 UTC#30482duplicateconfirmednews
Spero Therapeutics secures ex-China rights to Innovent's antibody therapy in $1.1B deal
2026-07-14 10:43:06 UTC#29914duplicateconfirmednews
Spero Therapeutics licenses Innovent's IBI355 autoimmune drug in deal worth up to $1.1 billion
reutersimportance 0.40trust 0.90Spero Therapeutics, Inc. +0.40Innovent Biologics, Inc. +0.30IBI355 +0.30